Navigation Links
Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
Date:8/22/2011

organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or othe
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
2. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
3. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
4. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
5. Delcath on Preliminary List of Additions to Russell Microcap® Index
6. Delcath to Present at the JMP Securities Research Conference
7. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
8. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
9. Delcath to Update Investors on FDA Meeting
10. Delcath Expands Board of Directors With Appointment of Gabriel Leung
11. Delcath to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... its pro forma net operating loss (NOL) guidance and ... financial position.  Isis, significantly improved financial results were due ... in payments the Company received from its partners.  Isis, ... a nearly 60% improvement over its 2013 NOL of ...
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... , February 27, 2015 ... new study showing you trends, R&D progress, and predicted ... heading? What are the commercial prospects for this ... you potential revenues and other trends to 2025, discussing ... report lets you assess regenerative medicine : cell-based ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... Vancouver, BC (PRWEB) February 28, 2015 Vancouver ... several personal injury claims are affected by time limits. They ... can weaken a person’s claim or even nullify it. Many ... adverse effects on a client’s rights under BC law. As ... who are affected by accidents should consult a personal injury ...
(Date:2/28/2015)... February 28, 2015 For those people ... person, the Mesothelioma Applied Research Foundation (Meso ... Tuesday, March 3, starting at 9:30 AM. , The ... registration. The broadcast can be accessed through any browser ... . , The Symposium is a unique event that ...
(Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
(Date:2/28/2015)... February 28, 2015 A case management ... lawsuits that have been filed by law firms including ... week in March, the Firm notes. , According ... involved in the federal litigation will meet on March ... to prescription therapy treatments designed to raise levels of ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... and anxiety are the heaviest smokers in the country, but ... assume that if their patients try to quit smoking, their ... a myth, according to Brian Hitsman, a tobacco addiction specialist ... School of Medicine. He also is a member of the ...
... Growing evidence shows that exposure to lead in the ... of hypertension. However, those studies have looked at lead ... of cumulative lead exposure over time. In a new ... (HSPH) and the University of Michigan School of Public ...
... a new report, University of Illinois professor Barbara H. Fiese urges ... family mealtimes as a matter of public policy. "There are ... their families as taking 18 to 20 minutes to eat together ... said Fiese, a U of I professor of human development and ...
... , , , ... of the nation,s leading experts in asthma, has been ... Erzurum will collaborate with experts in nuclear medicine and ... observe changes in the lungs of patients during an ...
... WASHINGTON, Sept. 9 As Obama prepares to address the nation ... nation,s Catholic bishops to be prepared to shut down Catholic health ... compromising with the intrinsic evils currently contained in various Obamacare proposals. ... ) , , "Obama speaks tonight. ...
... , BOSTON, Sept. 9 A ... a result of laboratory use and confinement. Developmental Context ... published in the September issue, Vol. 45 (5), of the ... . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090909/DC72238 ) ...
Cached Medicine News:Health News:Doctors fear asking mentally ill to quit smoking 2Health News:Doctors fear asking mentally ill to quit smoking 3Health News:Lead in bone associated with increased risk of death from cardiovascular disease in men 2Health News:U of I acientist: Public policy should promote family mealtimes 2Health News:U of I acientist: Public policy should promote family mealtimes 3Health News:$750,000 Awarded for Cutting-Edge Asthma Research to 'See' Changes in the Lungs During an Attack 2Health News:A.L.L.: Bishops Must Choose Between Christ-Centered Care and Obamacare 2Health News:Chimpanzees Suffer Psychologically Like Humans 2Health News:Chimpanzees Suffer Psychologically Like Humans 3
The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe...
... Alsius heat exchange catheters connect to the ... and maintains a target temperature input by ... patient core temperature and automatically adjusts the ... catheter (0-42C), providing consistent maintenance of temperature. ...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 21 gage needle stick is desired....
Medicine Products: